The amyloid precursor protein (APP) binds the PIKfyve complex and modulates its function by Currinn, Heather & Wassmer, Thomas
1 
 
The Amyloid Precursor Protein (APP) binds the PIKfyve complex and modulates its 
function. 
Heather Currinn and Thomas Wassmer 
 
 
 
Authors for correspondance: 
H. Currinn: currinnh@aston.ac.uk 
T. Wassmer: twassmer@hotmail.com 
 
School of Life and Health Sciences 
Aston University 
Birmingham B4 7ET 
United Kingdom 
 
 
 
2 
 
Abstract 
Phosphoinositides are important components of eukaryotic membranes that are required for 
multiple forms of membrane dynamics. Phosphoinositides are involved in defining 
membrane identity, mediate cell signalling and control membrane trafficking events. Due to 
their pivotal role in membrane dynamics,  phosphoinositide deregulation contributes to 
various human diseases.  
In this review we will focus on the newly emerging regulation of the PIKfyve complex, a 
phosphoinositide kinase that converts the endosomal phosphatidylinositol-3-phosphate 
(PI(3)P) to phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2), a low abundance 
phosphoinositide of outstanding importance for neuronal integrity and function. Loss of 
PIKfyve function is well known to result in neurodegeneration in both mouse models and 
human patients. 
Our recent work has surprisingly identified the Amyloid Precursor Protein (APP), the central 
molecule in Alzheimer's disease aetiology, as a novel interaction partner of a subunit of the 
PIKfyve complex, Vac14. Furthermore, it has been shown that APP modulates PIKfyve 
function and PI(3,5)P2 dynamics, suggesting that the APP gene family functions as regulator 
of PI(3,5)P2 metabolism. The recent advances discussed in this review suggest a novel, 
unexpected, beta amyloid independent mechanism for neurodegeneration in Alzheimer's 
disease.  
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Phosphoinositide metabolism and the PIKfyve complex 
Phosphoinositides are important components of cellular membranes. What sets them 
apart from other phospholipids is their potential for conversion into different species by 
phosphorylation or dephosphorylation of the inositol head group by various, organelle-
specific kinases and phosphatases. This allows phosphoinositides to assume specific 
subcellular localisations and allows them to fulfil their functions in an organelle-specific 
manner.  
Phosphoinositides fulfil a plethora of important roles. A key aspect is their ability to 
provide membrane attachment for phosphoinositide binding proteins (1). Their membrane 
specific localisation, combined with localised production or breakdown of phosphoinositide 
species can control membrane association of effectors or their activation in a temporally and 
spatially defined manner. These principles are well illustrated by membrane association of 
the protein kinase Akt/PKB by binding PI(3,4,5)P3 upon activation of receptor tyrosine 
kinases (2). This generic mechanism has been adopted in a plethora of biological processes 
(3, 4).  
This review will focus on the regulation of a kinase complex, known as the PIKfyve 
complex that produces the low abundance phosphoinositide PI(3,5)P2 (reviewed in (5–8)). 
This species was shown to be of outstanding physiological significance for the maintenance 
of the central and peripheral nervous systems (CNS and PNS) (9–11). The regulation of the 
PIKfyve complex is currently beginning to emerge with fascinating implications for our 
understanding of neurodegenerative disorders such as Alzheimer’s disease. 
The PIKfyve kinase (also known as Fab1) converts endosomally localised PI(3)P to 
PI(3,5)P2 by phosphorylation of the 5-hydroxyl group of the inositol ring (12). PIKfyve acts 
as part of a larger complex that in metazoa consists of PIKfyve, Vac14 (also known as 
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ArPIKfyve) and Fig4 (Sac3) (6, 13–15). PI(3,5)P2 can be dephosphorylated to yield PI(3)P by 
Fig4 which has an interesting dual role as activator of PIKfyve as well as a PI(3,5)P2 specific 
phosphatase (16). PI(3,5)P2 can also be dephosphorylated by myotubularin 3 to yield PI(5)P 
and has been argued to represent the major source of PI(5)P (17). By consequence, 
inactivation of PIKfyve will have both PI(3,5)P2 and PI(5)P dependent effects (11).  
Work from the Weisman and Meisler labs has demonstrated that inactivation of any 
of the subunits of the PIKfyve complex leads to significant drops of PI(3,5)P2 levels and 
pronounced neurodegeneration in mouse models and human patients (9–11). Specifically, 
loss of function mutations in Fig4 and Vac14 have been shown to lead to rare variants of 
Amyotrophic Lateral Sclerosis (ALS) and Marie-Charcot-Tooth syndrome in patients, 
necessitating to understand the functions of PI(3,5)P2 and how it is regulated (10, 18). 
Cellular functions of the PIKfyve complex 
On a cellular level the most noticeable defect upon impaired PIKfyve function is the 
formation of swollen ‘vacuoles’, easily visible at low magnification in living cells, presumed 
to stem from the endosomal system (19). Dysfunction of the endo- and lysosomal TRP-
channel TRPML-1 (also known as mucolipin-1) significantly contributes to vacuole 
formation (20). PI(3,5)P2 binds to this channel and controls its conductivity (20). Lack of 
PI(3,5)P2 reduces TRPML-1 conductivity and appears to disrupt the fusion and fission cycle 
of endosomes and lysosomes (21). Interestingly, mutations of TRPML-1 lead to 
mucolipidosis type IV, a lysosomal storage disease resulting in childhood neurodegeneration 
(21). 
Loss-of-PIKfyve function also disrupts endosomal receptor sorting, with a particularly 
strong effect on endosome to Golgi traffic (22–24). Other sorting events such as ESCRT 
dependent EGF receptor downregulation do not seem to be majorly affected (22). 
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PIKfyve can also modulate kinase activity. Recently the raptor subunit of the mTOR 
complex 1, a major signalling hub controlling catabolic and anabolic processes from the 
surface of the lysosome was shown to bind PI(3,5)P2 and require PIKfyve activity for 
signalling to its downstream effector S6 kinase (25). However, in a study by Wang et al. 
PIKfyve inhibition using Apilimod failed to suppress mTOR signalling to S6 kinase (26). 
The yeast homologue of PIKfyve (Fab1) has also been suggested to regulate the 
vacuolar H+-ATPase (V-ATPase) by controlling its assembly state (27). This enzyme 
controls acidification of the yeast vacuole, the functional equivalent of lysosomes in higher 
organisms. While Ho et al. did not find any major effect on vacuolar pH under steady state 
conditions, they confirmed that Fab1 is required for controlling vacuolar pH under osmo 
stress (28), known to boost PIKfyve activity and PI(3,5)P2 levels (29). So both studies agree 
on the fact that Fab1 may affect vacuolar pH at least under conditions that require enhanced 
Fab1 activity. This is interesting as the V-ATPase is of great importance for endosomal 
sorting, receptor downregulation and the activity of acidic hydrolases in lysosomes (30). 
Unsurprisingly, loss of V-ATPase function also strongly disrupts autophagy (31). 
 
The Amyloid Precursor Protein (APP) binds to and regulates PIKfyve function 
The amyloid precursor protein (APP) is a type 1 transmembrane protein best known 
for its role in Alzheimer’s disease. It belongs to the APP gene family, consisting of APP, 
APLP1 and APLP2, that exhibit a certain degree of functional redundancy (32). The APP 
gene lies on chromosome 21 and can be alternatively spliced to produce three isoforms.  APP 
is ubiquitously expressed in mammalian cells with each isoform expressed at varying levels 
depending on tissue and cell type (32, 33).  
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APP is well known to be cleaved by secretases in Alzheimer’s disease, first by the 
rate limiting β-secretase (known as BACE-1) in endosomes and lysosomes (34). The C-
terminal C99 peptide, released upon β-secretase cleavage, is further cleaved by γ-secretase 
into Aβ and APP’s intracellular domain (known as AICD) (34). APP can also be processed in 
a non-amyloidogenic way, first by cleavage of APP by α-secretase in the middle of the Aβ 
peptide sequence, followed by γ-secretase cleavage (34).  
Despite APP’s role in Alzheimer’s disease its physiological role still remains largely 
unclear, as research has been focused heavily on the neurotoxic Aβ.  APP has been linked to 
numerous physiological processes including cell adhesion, neurite outgrowth and 
synaptogenesis (reviewed in (35)). APP is thought to play a role in cell signalling as its 
proteolytic processing resembles that of the Notch receptor; AICD has also been proposed to 
translocate to the nucleus and alter gene expression (36).  
The intracellular trafficking of APP is probably important for its physiological 
function and plays a role in APP’s proteolytic processing. APP is produced in the 
endoplasmic reticulum followed by several post translational modifications in the Golgi, 
including glycosylation, phosphorylation and ubiquitination (34). APP is then trafficked to 
the plasma membrane via the constitutive secretory pathway (34).  APP is also known to 
traffic from the Trans-Golgi-Network (TGN) to lysosomes in an AP-3 dependent manner 
(37). APP also traffics from the TGN to endosomes using AP-4 (38). Retrograde trafficking 
of APP from the endosomes to the TGN depends on its binding partner SorLA (39, 40), a 
member of the  VPS10 receptor family, acting as an adaptor for retromer binding to APP 
(41). Interestingly, loss of VPS35 causes an increase of APP in endosomes and a decreased 
APP half-life (42). In a mouse model of Alzheimer’s disease, the hemizygous deletion of 
VPS35 was shown to accelerate neuropathophysiology (43), suggesting that APP 
accumulation in the endosomal system may play a role in Alzheimer's disease. The transport 
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of the β-secretase BACE-1 from the endosomes to the TGN is also retromer dependent (44). 
Loss of VPS35 reduces the retrieval of both APP and BACE-1 back to the TGN, leading to 
an increase of aberrant APP processing (42). Endosome to TGN transport of a number of 
retromer-dependent and retromer-independent routes requires PIKfyve (22). 
Using a recently developed methodology for analysing the interactome of the 
intracellular domains of transmembrane receptors using proteo-liposomes we surprisingly 
identified the PIKfyve complex as a putative interactor of the APP intracellular domain (45, 
46). We analysed this interaction in detail and found that the highly conserved YENPTY 
motif of the APP intracellular domain is crucial for directly binding the Vac14 subunit of the 
PIKfyve complex (46). Using a novel PI(3,5)P2 specific probe (47) we showed that 
overexpression of APP or ACID increased the number of PI(3,5)P2 positive vesicles in both 
HeLa and SH-SY5Y neuroblastoma cells. Conversely, knock-down of APP or the APP 
paralogue APLP2 reduced the number of PI(3,5)P2 positive vesicles in HeLa cells, suggesting 
that APP and its paralogues APLP2 are both able to stimulate PIKfyve function (46). RNAi 
Suppression of APP and APLP2 also increased the number of cells that display vacuoles, 
similar to the phenotype observed with PIKfyve RNAi, although to a lower extent (22, 46). 
Moreover, APP and APLP2 joint suppression sensitised cells for vacuole formation when 
PIKfyve was inhibited for a brief amount of time (46). While so far we have not been able to 
measure PI(3,5)P2 levels biochemically, all our cell biological findings suggest that APP gene 
family members modulate PIKfyve function.  
It is important to bear in mind that PIKfyve activity is necessary for both the 
formation of PI(3,5)P2 and PI(5)P (11), a significant hurdle for defining which of the cellular 
effects of PIKfyve depend on PI(3,5)P2 and which on PI(5)P.  
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We also tested whether the APP/PIKfyve interplay is conserved in evolution using the 
C. elegans genetic model. A genetic analysis of the function of the APP orthologue APL-1 
revealed that the APL-1 C-terminus is required for PIKfyve (PPK-3 in C. elegans) function 
required for endosomal homeostasis and neuronal function (45), entirely consistent with the 
data obtained in mammals. 
Together these studies showed that APP family members bind the PIKfyve complex 
and control its function, shedding light on the elusive functions of the APP gene family. Both 
studies suggest that the APP family members function as activators of the PIKfyve complex. 
The fact that APP, a type I transmembrane receptor that traffics between the Golgi, 
plasma membrane and the endosomal system, can bind to and modify PIKfyve function has 
interesting implications. What is the purpose of a receptor, cycling through an organelle, 
being able to modify the phosphoinositide composition of this organelle? An interesting 
answer was provided when we noticed that PIKfyve inhibition led to the trapping of APP in 
EEA1 positive early endosomes (37), showing that APP trafficking requires PIKfyve activity. 
This would suggest that APP, upon arrival in early endosomes is able to bind the PIKfyve 
complex and stimulate PI(3,5)P2 formation, promoting its own sorting and thus escaping from 
early endosomes. The most likely destination for APP sorted from endosomes is the trans-
Golgi-network, as endosome to TGN transport has been shown to be one of the key functions 
of the PIKfyve complex (22).  
This is an interesting example of a receptor that has the potential to actively contribute 
to its own sorting by an interaction with a phosphoinositide kinase complex. It remains to be 
explored whether this may be an example of a more widespread principle or whether the 
APP/PIKfyve interplay represents a truly special relationship. 
The APP/PIKfyve interplay in Alzheimer’s disease. 
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The fact that APP can modulate PIKfyve function has important implications for the 
molecular mechanism of neurodegeneration in Alzheimer’s disease. Loss of PIKfyve 
function in mouse models has been demonstrated to result in serious neurodegeneration (9–
11)⁠. For example, knock-out of Vac14 led to perinatal death of mouse pups. Closer analysis 
of brain sections highlighted extensive neurodegeneration, the appearance of aberrant 
vacuoles and apoptosis (9, 10). These observations were paralleled by the identification of a 
loss-of-function mutation in the Fig4 gene, which also resulted in significant, post-natal 
neurodegeneration in the CNS and PNS (10). More recently it was shown that a strong 
reduction of PIKfyve expression seriously affects the integrity of the CNS as well, but has 
additional deleterious effects on the heart, lungs, kidneys and other organs in mice, consistent 
with the ubiquitous expression of the PIKfyve complex subunits (11). These findings 
highlight that loss of function of the kinase subunit, e.g. PIKfyve causes more widespread 
defects than loss of its accessory subunits Vac14 and Fig4, suggesting that CNS and PNS are 
exquisitely sensitive to perturbations of PI(3,5)P2 metabolism, more so than other organs and 
tissues. 
A key event in Alzheimer’s disease is the proteolytic destruction of APP by beta and 
gamma secretase cleavage mainly in the endosomal system (34). Mutations in the APP gene 
or the gamma secretase complex identified in patients suffering from familial (also known as 
early onset) Alzheimer’s disease document that aberrant APP cleavage by gamma secretase is 
sufficient to cause the disease (48, 49). Importantly, the intracellular domain of APP, released 
by gamma secretase cleavage is rapidly broken down, resulting in a very short lifetime of this 
fragment (50). As cleavage of APP by secretases is crucial for the development of 
Alzheimer’s disease and as one cleavage product, beta-amyloid, accumulates in patients' 
brains, this led to the conclusion that beta amyloid production is the driving force in 
Alzheimer’s disease (51). This view seemed to be strengthened by the fact that patients with 
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trisomy 21, on which the APP gene is located, almost invariably develop signs of 
neurodegeneration and accumulate beta amyloid (52). This was presumed to stem from a 
dosage effect of APP overproduction due to the extra copy of chromosome 21. However, a 
closer analysis of APP metabolism showed that in Down syndrome patients BACE1 activity 
is increased while the APP protein level appeared unchanged, suggesting that enhanced APP 
cleavage rather than overproduction of APP drives neurodegeneration in Down's syndrome 
(53). So data from both familial Alzheimer’s disease and Down syndrome patients suggest 
that enhanced APP cleavage is the central event in Alzheimer’s disease. It is currently widely 
assumed that the overproduction of beta amyloid initiates a cascade of deleterious events that 
ultimately results in neurodegeneration. 
However, the fact that APP can bind to the PIKfyve complex and stimulate its 
function may suggest an entirely different explanation for neurodegeneration in Alzheimer’s 
disease: Cleavage of APP by the gamma secretase releases APP’s intracellular domain that is 
necessary for binding to and activating the PIKfyve complex (46). APP's intracellular 
domain, after cleavage, is followed by its rapid degradation (50). Thus enhanced gamma 
secretase cleavage would prevent APP from binding to and stimulating PIKfyve function, 
disrupting endosomal sorting and homeostasis. It is worth noting that endosomal 
abnormalities, especially an enlargement of EEA1 positive early endosomes, is an early 
pathological hallmark observed in Alzheimer’s disease (54). Reduced PIKfyve function is 
known to result in defective neuronal function and neurodegeneration, as demonstrated by 
mouse models and human patients suffering from rare forms of Charcot-Marie-Tooth 
syndrome and ALS (18, 55). How PIKfyve dysfunction exactly causes neurodegeneration is 
still not fully understood, however, with the identification of additional PI(3,5)P2 effectors 
this is becoming clearer. The previously mentioned PI(3,5)P2/TRPML-1 interplay required 
for the fusion/fission cycle of endosomes with lysosomes and for successful completion of 
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autophagy is most likely to contribute to the neurodegenerative phenotype (56). Impairment 
of autophagy is well documented to result in neurodegeneration (57). PI(3,5)P2 may also 
control V-ATPase function and endo/lysosomal acidification (18) which is crucial for the 
lysosomal breakdown of multiple substrates and for the successful completion of autophagy, 
and could therefore contribute to the neurodegenerative phenotype as well. 
Disruption of endo/lysosome and autophagosome function caused by the lack of 
activation of multiple PI(3,5)P2 effectors may also explain the toxic built up of molecules 
such as beta amyloid and hyperphosphorylated Tau, both characteristic of Alzheimer’s 
disease (58). This hypothesis is illustrated in Figure 1. 
 This alternative neurodegeneration model raises the question whether the 
accumulation of beta amyloid is in fact a consequence resulting from an underlying 
endo/lyso/autophagosomal pathology rather than its cause. If this is the case then targeting 
beta amyloid production or aggregation may be of limited therapeutic effect. This is 
consistent with the failure of all published clinical drug trials that aim to block aggregation or 
increase solubility of beta amyloid to stop the progression of late onset Alzheimer’s disease 
(59).  
It will be extremely interesting to test whether evidence of PIKfyve dysfunction can 
be detected in early or late onset Alzheimer’s disease and whether this could explain aspects 
of the neurodegenerative phenotype. If so this would make the PIKfyve pathway an 
interesting drug target not only in Alzheimer’s disease but also in a other neurodegenerative 
diseases with strong endo/lyso/autophagosomal pathology.  
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Figure 1 
 
Figure 1) Working model exploring what role the APP/PIKfyve interplay may play in 
Alzheimer's disease 
Under normal conditions, APP binds to and activates the PIKfyve complex to enable sorting 
events such as endosome to TGN transport as well as maturation of endosomes and fusion 
with lysosomes, allowing lysosomal breakdown of proteins destined for degradation. 
However, in Alzheimer's disease APP falls prey to excessive cleavage by beta and gamma 
secretases, thereby releasing the cytoplasmic domain of APP (necessary for binding the 
PIKfyve complex) from the endosomal membrane, followed by its rapid breakdown (50). 
This will reduce PIKfyve activity which is known to result in neurodegeneration by 
mechanisms that are currently not entirely clear (9–11)⁠. Reduced PIKfyve activity will 
impair endosome to TGN transport and the fusion/fission cycle of late endosomes and 
lysosomes controlled by TRPML-1 (22, 60)⁠. Interestingly, the relevance of retromer 
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mediated endosome to TGN transport in Alzheimer's disease has been highlighted previously 
(43)⁠. Disruption of endo/lysosomal fusion will reduce the capability of neurons to degrade 
toxic proteins such as beta amyloid and hyperphosphoryalted tau, resulting in their 
accumulation. These will be released from neurons either when neurons are dying or by 
fusion of late endosomes with the plasma membrane, for example during the release of 
exosomes (60).⁠⁠ 
